Mereo BioPharma Receives Nasdaq Notice for ADS $1.00 Bid-Price Noncompliance

What Happened
Mereo BioPharma Group plc (MREO) filed an 8-K on August 19, 2026 reporting that Nasdaq’s Listing Qualifications staff notified the company it failed to meet the $1.00 minimum bid-price requirement under Nasdaq Listing Rule 5550(a)(2). The company previously received a First Notice on February 17, 2026 with an initial 180‑day cure period (through August 17, 2026). On August 18, 2026 the company received a Second Notice granting an additional 180‑day compliance period through February 16, 2027. If the ADS closing bid is at least $1.00 for 10 consecutive business days during the Second Compliance Period, Nasdaq will confirm compliance; otherwise Nasdaq may issue a delisting notice (subject to appeal).

Key Details

• Rule cited: Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price).
• First Notice: February 17, 2026 — initial cure period to August 17, 2026.
• Second Notice: August 18, 2026 — additional cure period to February 16, 2027.
• Compliance condition: closing bid ≥ $1.00 for at least 10 consecutive business days; failure to comply may lead to delisting (company may appeal).
• Filing signed by Charles Sermon, General Counsel, dated August 19, 2026. The notices do not have any immediate effect on the ADS listing.

Why It Matters
This filing signals a material listing-risk event: if Mereo does not regain the $1.00 ADS bid price within the cure period, Nasdaq could move to delist its ADSs, which can reduce liquidity and make trading or raising capital more difficult. Investors should monitor the ADS closing price, company updates and subsequent SEC filings for progress on compliance or any plans the company implements to address the deficiency. The company also highlighted standard forward‑looking risk factors (e.g., cash sufficiency, clinical and regulatory risks, reliance on partners) in the filing.